| Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know |
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2025-05-16 14:05:25 |
Czytaj oryginał (ang.) |
| 2 Game-Changing Additions To Your Retirement Income Portfolio |
Retirement income investing should prioritize risk management, income stability, and capital preservation over aggressive growth strategies. To achieve that, investors tend to allocate high-quality value. For example, REITs, infrastructure, midstream and utilities are typical asset classes here. |
seekingalpha.com |
2025-05-16 13:15:00 |
Czytaj oryginał (ang.) |
| Here's How Many Shares of Pfizer You Should Own to Make $10,000 in Annual Dividend Income |
Looking for income? You might want to check out Pfizer (PFE 2.57%). |
fool.com |
2025-05-16 08:49:00 |
Czytaj oryginał (ang.) |
| US House panel seeks information from Pfizer over alleged COVID vaccine delay |
U.S. lawmakers on Thursday asked Pfizer Inc for information on alleged comments by a former executive suggesting its research executives intentionally delayed clinical trial results of its COVID-19 vaccine to influence the 2020 presidential election. |
reuters.com |
2025-05-15 21:18:47 |
Czytaj oryginał (ang.) |
| New allegations about timing of Pfizer Covid vaccine passed to House panel |
A former Pfizer scientist said the timing of the 2020 vaccine results “wasn't a coincidence,” according to allegations provided by a rival drugmaker. |
wsj.com |
2025-05-15 15:20:00 |
Czytaj oryginał (ang.) |
| 5 Low Price-to-Book Value Stocks to Buy in May |
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and SAN are some such stocks. |
zacks.com |
2025-05-15 13:41:13 |
Czytaj oryginał (ang.) |
| Dividend Harvesting Portfolio Week 219: $21,900 Allocated, $2,206.52 In Projected Dividends |
I'm bullish on the second half of 2025, expecting further market gains if CPI trends lower and trade talks progress positively. Despite a small portfolio decline this week, my Dividend Harvesting Portfolio continues to meet its goals of generating recurring income and mitigating downside risk. Reinvesting dividends and strategic additions to undervalued positions have driven forward annualized dividend income above $2,200, with $2,500 in sight for 2025. |
seekingalpha.com |
2025-05-15 13:00:00 |
Czytaj oryginał (ang.) |
| 3 Magnificent S&P 500 Dividend Stocks Down 62%, 63%, and 64% to Buy and Hold Forever |
With China and the United States finally talking to one another regarding tariffs, there's a glimmer of hope on the macroeconomic horizon. Investors might want to continue thinking and acting defensively though, given that we still don't exactly what the future holds. |
fool.com |
2025-05-14 22:05:00 |
Czytaj oryginał (ang.) |
| Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer |
Ongoing tariff disputes and President Trump's drug pricing order heighten uncertainties for AbbVie Inc. and Pfizer Inc. The more uncertain the time, the more investors should focus on return vectors that are less ambiguous. ABBV's superior dividend track record, safer payout ratio, consistent share buybacks, and robust margins make it an overall better package compared to PFE. |
seekingalpha.com |
2025-05-14 20:36:16 |
Czytaj oryginał (ang.) |
| EU court annuls rejection of bid for EU's von der Leyen vaccine messages with Pfizer |
Europe's second-top court on Wednesday dismissed the European Commission's rejection of a New York Times' request to access text messages between its President Ursula von der Leyen and Pfizer CEO Albert Bourla on the purchase of billions of euros of COVID-19 vaccines. |
reuters.com |
2025-05-14 07:41:13 |
Czytaj oryginał (ang.) |
| PFE vs. LLY: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-05-13 16:45:41 |
Czytaj oryginał (ang.) |
| 4 Value Picks to Ride the Market Rebound After US-China Trade Thaw |
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. STNE, CNC, CVS & PFE boast a low P/CF ratio. |
zacks.com |
2025-05-13 15:40:33 |
Czytaj oryginał (ang.) |
| Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order. |
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say. |
barrons.com |
2025-05-13 15:18:00 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Pfizer (PFE) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-05-13 14:45:47 |
Czytaj oryginał (ang.) |
| US-China Talks Spark Optimism; Betting Markets See Recession Odds Drop |
A surprising thaw in US-China trade relations sparked significant optimism on Wall Street Monday. This positive development, coupled with lower recession odds, sets up a bullish long-term outlook for investors. |
zacks.com |
2025-05-13 14:01:09 |
Czytaj oryginał (ang.) |
| Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared |
President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices. |
zacks.com |
2025-05-13 12:40:53 |
Czytaj oryginał (ang.) |
| 50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy |
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies, including Pfizer and Nordstrom, met the "safer" qualification with free cash flow yields exceeding dividend yields. Analysts estimate net gains of 19.58% to 41.46% for top Fortune 50 WMA companies by May 2026, with Novo Nordisk leading. |
seekingalpha.com |
2025-05-12 22:25:11 |
Czytaj oryginał (ang.) |
| Drugmakers are spared worst-case drug pricing scenario for now |
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan. |
wsj.com |
2025-05-12 17:14:00 |
Czytaj oryginał (ang.) |
| Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices |
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices. |
youtube.com |
2025-05-12 16:36:24 |
Czytaj oryginał (ang.) |
| Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet |
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach. |
seekingalpha.com |
2025-05-12 16:30:03 |
Czytaj oryginał (ang.) |
| FDA Vaccine Panel Meeting To Discuss Flu Shots Reportedly Canceled |
A meeting of the Food and Drug Administration's vaccine advisory committee to discuss the next season's flu vaccine has reportedly been canceled, the second such disruption of a meeting involving vaccine policy experts at the federal level since prominent vaccine skeptic Robert F. Kennedy Jr took over as the Health and Human Services secretary earlier this month. |
forbes.com |
2025-02-27 04:53:56 |
Czytaj oryginał (ang.) |
| Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer |
SMMT's Q4 results meet estimates. The company signs a deal with Pfizer that expands ivonescimab's development beyond the NSCLC indication. |
zacks.com |
2025-02-25 11:40:34 |
Czytaj oryginał (ang.) |
| Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs |
HONG KONG , Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings. "Rapidly developing novel mechanisms that go beyond what is currently available to patients and physicians is what we believe will make the most significant impact for those facing the greatest challenges from cancer today," noted Bob Duggan and Dr. Maky Zanganeh, Summit's Co-CEOs. |
prnewswire.com |
2025-02-24 22:13:00 |
Czytaj oryginał (ang.) |
| Pfizer names former FDA director Patrizia Cavazzoni as chief medical officer |
Pfizer said on Monday former head of FDA's drug center, Patrizia Cavazzoni, will join the drugmaker as chief medical officer. |
reuters.com |
2025-02-24 13:31:01 |
Czytaj oryginał (ang.) |
| Pfizer: What The Summit Therapeutics Deal Brings |
Pfizer: What The Summit Therapeutics Deal Brings |
seekingalpha.com |
2025-02-24 12:53:50 |
Czytaj oryginał (ang.) |
| Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know |
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-02-24 12:05:37 |
Czytaj oryginał (ang.) |
| Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus |
Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic. |
zacks.com |
2025-02-24 11:30:27 |
Czytaj oryginał (ang.) |
| INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE) |
PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera. |
globenewswire.com |
2025-02-24 10:33:00 |
Czytaj oryginał (ang.) |
| Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here |
Despite significant market events, industrial and tech stocks have had similar returns since 2020, indicating a potential long-term rotation favoring value stocks. Higher inflation and interest rates are shifting the risk/reward balance towards value stocks, making them more attractive compared to growth stocks. The AI revolution and liquidity improvements temporarily boosted growth stocks, but these tailwinds may not sustain long-term outperformance. |
seekingalpha.com |
2025-02-24 09:30:00 |
Czytaj oryginał (ang.) |
| Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs) |
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings. “Rapidly developing novel mechanisms that go beyond what is currently available to patients and physicians is what we believe will make the most significant impact fo. |
businesswire.com |
2025-02-24 08:00:00 |
Czytaj oryginał (ang.) |
| Prediction: These Could Be the Best-Performing Value Stocks Through 2030 |
Buying quality stocks when they're unpopular can be very rewarding. |
fool.com |
2025-02-23 17:26:00 |
Czytaj oryginał (ang.) |
| 3 Ultra-High-Yield Dividend Stocks You Can Buy and Hold Forever |
I went to a Prince concert years ago. He opened with one of his hit songs from the '80s -- Let's Go Crazy. |
fool.com |
2025-02-23 06:53:00 |
Czytaj oryginał (ang.) |
| Pfizer: No More Growth - Still A Worthy Dividend Buy |
PFE's sell-off triggers a rich dividend yield of 6.73% and double digits capital appreciation prospects, thanks to management's focus to "enhancing long-term shareholder value." Despite the patent cliff headwinds and IRA Medicare Part D redesign impacts, its core portfolios and strategic acquisitions demonstrate robust growth profile, particularly in oncology. These developments underscore why the management's focus on intensified business developments and R&D efforts has been well justified. |
seekingalpha.com |
2025-02-22 11:00:00 |
Czytaj oryginał (ang.) |
| 3 Magnificent Dividend Growth Stocks With Yields Above 5% to Buy Now and Hold at Least a Decade |
There are many ways to make money on Wall Street, but some methods are a lot more reliable than others. Whether you're looking for a way to raise the stream of passive income your portfolio produces or you simply want to outperform benchmark averages, adding some dividend-paying stocks to your portfolio is a smart way forward. |
fool.com |
2025-02-22 05:57:00 |
Czytaj oryginał (ang.) |
| 2 No-Brainer Healthcare Stocks to Buy With $500 Right Now |
Looking for a good area in which to invest? Consider the healthcare sector. |
fool.com |
2025-02-21 07:50:00 |
Czytaj oryginał (ang.) |
| Pfizer says it will end global development of gene therapy Beqvez, Nikkei reports |
Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday. |
reuters.com |
2025-02-20 17:02:02 |
Czytaj oryginał (ang.) |
| Dividend Harvesting Portfolio Week 207: $20,700 Allocated, $2,010.09 In Projected Dividends |
The S&P 500 is up 3.96% YTD, and I predict it could reach 7,000 by the end of 2025. The Dividend Harvesting Portfolio reached a new milestone with a 28.65% ROI, generating $2,010.09 in forward annualized dividend income. I added to positions in Pfizer, Starwood Property Trust, and Reaves Utility Income Trust, focusing on undervalued stocks with strong dividend yields. |
seekingalpha.com |
2025-02-20 10:45:00 |
Czytaj oryginał (ang.) |
| The Smartest Dividend Stocks to Buy With $1,000 Right Now |
You have $1,000 (or $200 or $50,000) burning a hole in your pocket and you're itching to invest in some stocks. Might I suggest some dividend payers? |
fool.com |
2025-02-20 06:45:00 |
Czytaj oryginał (ang.) |
| 10 Ideal 'Safer' January Dividend Buys, Out Of 40 Choices From Readers |
Before January 31, 2025, my REaders mentioned 40 equities in their comments on my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers spoke-up about the ReFa/Ro. Ten analyst-target-estimated TOP-NET-GAIN ReFa/Ro: CAG, VZ, DOW, PFE, MRK GOGL, PK, PBR FRO, and TRMD averaged 40.36% net gains from reader data collected 2/17/25. Ten analysts target-augured January TOP-PRICE-UPSIDE reader faves & rogues (ReFa/Ro) were: CAG, VZ, PBR, DOW, PFE, GOGL, TRMD, PK, MRK, & FRO, boasting a 27.91% average target price upside estimate. |
seekingalpha.com |
2025-02-19 20:07:56 |
Czytaj oryginał (ang.) |
| Why Pfizer's Stock Price Isn't Reflecting Its True Value |
Pfizer's EPS and revenue beat my expectations, mainly due to strong sales of its anti-cancer medications. So, Xtandi sales amounted to $565 million in the fourth quarter of 2024, an increase of 79.9% year-on-year. A key contributor to its strong performance was its Vyndaqel family, whose sales grew more than 60% year over year. |
seekingalpha.com |
2025-02-19 09:22:23 |
Czytaj oryginał (ang.) |
| Is Pfizer Stock Undervalued at Current Prices? |
Pfizer (PFE -0.07%) stock investors are curious about the valuation and prospects for the healthcare company. |
fool.com |
2025-01-05 05:30:00 |
Czytaj oryginał (ang.) |
| High-Yield Dividend Stocks Rebound in 2025: These 5 Pay 5% and More |
Dividend stocks are a favorite among investors for good reason. They provide a steady income stream of passive income and offer a promising avenue for total return. |
247wallst.com |
2025-01-04 12:18:33 |
Czytaj oryginał (ang.) |
| Should You Buy Pfizer Stock Right Now in 2025? |
Pfizer (PFE 0.20%) is an interesting healthcare company with excellent prospects for cash flow growth. |
fool.com |
2025-01-03 14:16:00 |
Czytaj oryginał (ang.) |
| AUA Partners with Pfizer to Launch $1.5 Million RFP to Advance Care for Patients with Advanced Prostate Cancer |
BALTIMORE, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The American Urological Association Education and Research, Inc. (AUAER) is proud to announce a collaboration with Pfizer Medical Grants & Partnerships (GMGP) to offer $1.5 million in grant funding to urology and urologic oncology health institutions and organizations. This joint Request for Proposals (RFP) is designed to address critical gaps in patient care for individuals with advanced prostate cancer (APC) and support novel quality improvement, solution-based projects to address these challenges. |
globenewswire.com |
2025-01-03 12:46:00 |
Czytaj oryginał (ang.) |
| Pfizer Rises 5.6% in a Month: How Should You Play the Stock? |
Pfizer's PFE stock has risen 5.6% in the past month. This was due to the company's encouraging guidance for 2025 issued in mid-December 2025. |
zacks.com |
2025-01-03 12:01:47 |
Czytaj oryginał (ang.) |
| 3 Ultra-High-Yield Dividend Stocks That Are Screaming Buys in 2025 |
When the closing bell rang on Dec. 31, the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite had delivered respective returns of 13%, 23%, and 29% in 2024. The icing on the cake is that all three indexes achieved multiple record-closing highs. |
fool.com |
2025-01-03 07:21:00 |
Czytaj oryginał (ang.) |
| 10 Magnificent Stocks That Can Make You Richer in 2025 |
For a second straight year, investors have been given every reason to smile. As of this writing, with one trading day left in 2024, the iconic Dow Jones Industrial Average, benchmark S&P 500, and growth stock-powered Nasdaq Composite have respectively gained 13%, 24%, and 30%! |
fool.com |
2025-01-03 07:06:00 |
Czytaj oryginał (ang.) |
| The Zacks Analyst Blog Berkshire Hathaway, The Home Depot, Pfizer and AMREP |
Berkshire Hathaway, The Home Depot, Pfizer and AMREP are included in this Analyst Blog. |
zacks.com |
2025-01-03 05:46:22 |
Czytaj oryginał (ang.) |
| The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer |
Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog. |
zacks.com |
2025-01-03 05:46:16 |
Czytaj oryginał (ang.) |
| Pfizer (PFE) Advances While Market Declines: Some Information for Investors |
In the latest trading session, Pfizer (PFE) closed at $26.61, marking a +0.3% move from the previous day. |
zacks.com |
2025-01-02 21:19:17 |
Czytaj oryginał (ang.) |
| Here's Why Pfizer (PFE) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-01-02 13:07:44 |
Czytaj oryginał (ang.) |
| 5 Large Drug Stocks to Keep An Eye On in the New Year |
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio. |
zacks.com |
2025-01-02 12:02:09 |
Czytaj oryginał (ang.) |
| Got $5,000? These 3 Stocks Are Absurdly Cheap Buys Heading Into 2025 |
The stock market enjoyed a strong year in 2024 as the S&P 500 hit new records. The challenge for investors looking to get into the market amid such a strong bull run, however, is that valuations for some stocks have gotten high, perhaps even wildly overpriced. |
fool.com |
2025-01-02 09:30:00 |
Czytaj oryginał (ang.) |
| Top 3 Stocks Seeing a Spike in Call Option Volume |
Volume is what drives the entire market, and that is a fact that often gets lost in the sea of indicators, patterns, and trend lines that dominate today's concept of analysis. However, most investors fail to realize that these indicators and patterns are nothing more than price action recognition, and what drives price action is volume. |
marketbeat.com |
2025-01-02 09:16:16 |
Czytaj oryginał (ang.) |
| Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics |
Collaboration will leverage Atavistik Bio's proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated targets Atavistik Bio has rapidly identified novel, functional, allosteric binding pockets across a broad range of intractable target classes Collaboration with Pfizer will enable Atavistik Bio to extend the reach of its platform to potentially address a broader range of oncology indications, while simultaneously progressing its internal pipeline of precision oncology small molecule therapies CAMBRIDGE, Mass., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Atavistik Bio, a biotechnology company committed to discovering the next generation of precision allosteric therapeutics inspired by the body's natural regulators, today announced that it has entered into a research collaboration with Pfizer to accelerate the discovery of novel precision allosteric therapeutics to address significant unmet medical needs. |
globenewswire.com |
2025-01-02 09:00:00 |
Czytaj oryginał (ang.) |
| ChatGPT picks 5 undervalued stocks to watch at the start of 2025 |
Warren Buffett, one of the most famous investors of all time, made his billions with a getting rich slowly strategy and cleverly finding resilient and promising but undervalued businesses. |
finbold.com |
2025-01-01 12:15:00 |
Czytaj oryginał (ang.) |
| Pfizer's 2025 Comeback: What's Driving Growth |
Pfizer targets $4 billion in operational savings by 2024, improving margins and driving long-term profitability. PFE returned $7.1 billion via dividends in 9M-24, while reducing debt by $4.4 billion through balance sheet optimization. Investing $10.7-$11.7 billion in R&D, focusing on obesity treatments, oncology, and vaccines to address unmet needs. |
seekingalpha.com |
2025-01-01 11:15:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact |
The small-cap won't receive an expected payout in the first quarter, creating a cash overhang. |
marketwatch.com |
2024-12-31 13:22:00 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact |
Sangamo Therapeutics (SGMO) shares cratered more than 50% Tuesday, a day after the biopharma firm announced that Pfizer (PFE) had pulled out of its deal to co-develop a hemophilia drug. |
investopedia.com |
2024-12-31 13:20:39 |
Czytaj oryginał (ang.) |
| Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact |
On Monday, Sangamo Therapeutics, Inc. SGMO regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc PFE. |
benzinga.com |
2024-12-31 11:14:19 |
Czytaj oryginał (ang.) |